First global data, from Rosetta Lung-02 in first-line NSCLC, tell a familiar story.
ApexOnco Front Page
Recent articles
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
No sooner does one gammadelta-focused biotech die than another takes its place.
Full US approval of Gilead’s Tecartus was the only positive decision last month.
The Viktoria-1 trial of gedatolisib is a hit in PIK3CA-mutant, as well as in wild-type disease.
ASCO looms, while FDA decisions are due on Enhertu and Inqovi.
The two companies have been involved in recent licensing deals.
MK-6837 has been discontinued, the company discloses.
